Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 2,265 shares at $68.91 ($157K) on 2026-04-06, disclosed to the SEC on 2026-04-08.
Scheduled sale ($157k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.91 | 822 | $57K | 36.0% |
| 2 | $69.75 | 1,443 | $101K | 64.0% |
| Total | $69.45 avg | 2,265 | $157K | 100% |
| Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |